This candidate is in preclinical stages of development currently for the treatment of Triple Negative Breast Cancer. We also expect to develop it subsequently for a variety of other EGFR+ malignancies such as Colorectal, Head and Neck, Glioblastoma, Ovarian, Astrocytoma. Highly proliferative triple-negative breast cancers (TNBCs) have enhanced angiogenesis and vasculogenic mimicry that support rapid tumor growth and early metastases and have been found to have high levels of VEGF. Our antibody fusion candidate either alone or in combination with chemotherapeutic agent or anti-VEGF drugs is expected to be highly effective in treatment of such cancers. Anti-EGFR-TAP is efficacious in both in vitro and in in vivo TNBC xenografts in tumor inhibition, in decreasing metastasis and increasing survival of treated animals.
Anti-HER2-TAP is currently being studied in preclinical animal models as a therapeutic candidate for both HER2 positive breast cancer and ovarian cancer treatment. In breast cancer xenografts, the fusion has shown excellent inhibition of tumor growth, and significantly improved survival of the tumor-containing animals. Excellent tumor growth inhibition in ovarian cancer animal models by Anti-HER2-TAP has also been observed. Because of A-TAP’s long half-life and increased bioavailability in vivo, we expect positive outcome of the Anti-Her2-TAP fusion in clinical environment. Given the current results, and its differentiation from bevacizumab as an anti-angiogenic and VM-blocker, Anti-Her2-TAP is expected to be developed as a “biobetter” biological drug for breast cancer.
Disease is war with the laws of our being, and all war, as a great general has said, is hell.
--Lewis G. Janes